Skip to main content

Rare disease gene

Rare disease gene association discovery in the 100,000 Genomes Project


Up to 80% of rare disease patients remain undiagnosed after genomic sequencing1, with many probably involving pathogenic variants in yet to be discovered disease–gene associations. To search for such associations, we developed a rare variant gene burden analytical framework for Mendelian diseases, and applied it to protein-coding variants from whole-genome sequencing of 34,851 cases and their family members recruited to the 100,000 Genomes Project2. A total of 141 new associations were identified, including five for which independent disease–gene evidence was recently published. Following in silico triaging and clinical expert review, 69 associations were prioritized, of which 30 could be linked to existing experimental evidence.

The five associations with strongest overall genetic and experimental evidence were monogenic diabetes with the known β cell regulator3,4 UNC13A, schizophrenia with GPR17, epilepsy with RBFOX3, Charcot–Marie–Tooth disease with ARPC3 and anterior segment ocular abnormalities with POMK. Further confirmation of these and other associations could lead to numerous diagnoses, highlighting the clinical impact of large-scale statistical approaches to rare disease–gene association discovery.

Rare diseases collectively affect 3.5% to 5.9% of people worldwide5. Despite advances in genomic sequencing, molecular diagnosis continues to elude 50% to 80% of patients presenting to genetic clinics1. Furthermore, fewer than half of the 10,000 rare Mendelian diseases in the Online Mendelian Inheritance in Man (OMIM) database6 have an established genetic basis. Diagnostic failure may arise because of a lack of routine screening for non-coding7 or structural variants1. However, it is likely that a substantial proportion of the pathogenic variants responsible for patients undiagnosed with rare disease (cases) reside in those yet to be discovered genes associated with (possibly very rare) disorders.

The scale of rare disease sequencing studies, such as the Undiagnosed Disease Network8, Centers for Mendelian Genomics9, Deciphering Developmental Disorders10 and the 100,000 Genomes Project (100KGP)2, offers expanded opportunities to provide insight into pathogenic mechanisms of inherited disease, including the possibility of establishing disease–gene associations through case–control analyses, akin to methods used previously to identify common genetic variants influencing the risk of complex disorders. Such an approach provides much-needed power to identify genes harbouring rare pathogenic variants.

genetics awards, genomics, DNA research, hereditary science, gene editing, CRISPR recognition, genetic breakthroughs, medical genetics, population genetics, biotechnology awards, Nobel Prize in Genetics, genomic medicine, genetic innovation, molecular biology, personalized medicine, genetics research grants, bioinformatics, evolutionary genetics, genetic engineering, scientific excellence

#GeneticsAwards #Genomics #DNAResearch #HereditaryScience #GeneEditing #CRISPRRecognition #GeneticBreakthroughs #MedicalGenetics #PopulationGenetics #BiotechAwards #NobelPrizeGenetics #GenomicMedicine #GeneticInnovation #MolecularBiology #PersonalizedMedicine #GeneticsResearch #Bioinformatics #EvolutionaryGenetics #GeneticEngineering #ScientificExcellence

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Post-Stroke Cardiovascular risks

Study finds genetic factors key to post-stroke cardiovascular risks In a recent study published in the journal Stroke , researchers identify genetic and molecular risk factors for subsequent cardiovascular outcomes after incident stroke in an effort to identify potential therapeutic targets to improve patient prognoses. Identifying the causes of stroke Stroke is a major global health issue that causes significant disability and mortality, particularly arterial ischemic stroke (AIS). AIS, which is a type of stroke caused by blocked blood flow to the brain, is responsible for up to 85% of stroke cases. AIS arises due to cerebral blood vessel blockage, with modifiable risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, obesity, and lifestyle behaviors. Although genome-wide association studies (GWAS) often focus on incident strokes, studying subsequent events can provide new insights into stroke progression. Further research is crucial to identify genetic and...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more